Skip to main content
. 2019 Sep 25;9:953. doi: 10.3389/fonc.2019.00953

Table 1.

Ongoing clinical trials involving direct targeting of KRAS.

Compounds Company Mechanism Clinical trial
AMG 510 Amgen/Carmot Therapeutics KRASG12C inhibitor NCT03600883
MRTX849 Mirati (ex Array) KRASG12C inhibitor NCT03785249
KRAS TCR Gilead (ex Kite/NCI) Anti-KRASG12D engineered T-cell receptor NCT03745326
AZD4785 AstraZeneca/Ionis KRAS antisense oligonucleotide NCT03101839